標(biāo)題：求購藥品信息 詳細要求： 需求名稱：求購藥品信息 具體要求：求購全文 要求時間：近期需要 交稿方式：直接點擊交稿在線交稿就是了，我會每天過來看的，謝謝各位藥智的戰(zhàn)友們，價格可以商量   [更多]

藥智人才是最專業(yè)的醫(yī)藥產(chǎn)業(yè)招聘平臺，與許多醫(yī)藥行業(yè)的知名企業(yè)都有合作，職位種類豐富，崗位更專業(yè)~ 賺取賞金規(guī)則： 1.免費注冊/登錄藥智人才（https://job.yaozh.com/），上傳簡歷： 簡歷完善度≥80 可獲得10元賞金； 2.邀請朋友上傳簡歷（無上限） 朋友上傳簡歷完善度≥80 最高可獲得10000元賞金； 3.簡歷完成后，并截圖藥智人才簡歷板塊的完善度提交審核，并且備注藥智人才的用戶名/注冊手機信息； 4.審核通過后，賞金會在3個工作日內(nèi)審核，如提交后有刪除簡歷的行為，視為作弊處理,對應(yīng)賞金將會被凍結(jié)不予提現(xiàn)。 5.特別福利：簡歷完善后既有機會直接內(nèi)推給名企噢~ 溫馨提示： 1.如果疑問可以聯(lián)系客服QQ：3413833812 2.一經(jīng)發(fā)現(xiàn)求職者在上傳簡歷期間有作弊等行為，藥智人才將取消其賞金。 3.在法律允許的范圍內(nèi)，本活動一切解釋權(quán)歸藥智人才   [更多]

本團隊在進行藥理研究中發(fā)現(xiàn)瑞戈非尼與帕唑帕尼存在治療肺纖維化的潛力，且動物實驗藥效十分顯著，現(xiàn)二者針對肺纖維化適應(yīng)癥的專利申請已獲國家知識產(chǎn)權(quán)局受理。本團隊向意向進行瑞戈非尼、帕唑帕尼仿制生產(chǎn)的公司尋求合作，開發(fā)該藥物治療肺纖維化的新適應(yīng)癥，將技術(shù)轉(zhuǎn)化為產(chǎn)品，進行新藥注冊并上市。 若有開發(fā)該藥物新適應(yīng)癥的意愿，可聯(lián)系我們。   [更多]

1.Nihon Yakurigaku Zasshi. 2013 Jul;142(1):39-46. doi: 10.1254/fpj.142.39. Pharmacological and clinical properties of AIMIX combination tablets LD&HD, fixed-dose combination of irbesartan and amlodipine besilate. 2.Am J Cardiovasc Drugs. 2013 Apr;13(2):141-50. doi: 10.1007/s40256-013-0014-7. Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy. 3.Clin Ther. 2012 Aug;34(8):1705-19. doi: 10.1016/j.clinthera.2012.06.026. Epub 2012 Jul 30. I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. 4.Clin Ther. 2012 Aug;34(8):1720-34.e3. doi: 10.1016/j.clinthera.2012.07.001. Epub 2012 Jul 30. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. 5.Am J Cardiovasc Drugs. 2013 Apr;13(2):141-50. doi: 10.1007/s40256-013-0014-7. Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy. 6J Cardiol. 2019 Mar 20. pii: S0914-5087(19)30053-X. doi: 10.1016/j.jjcc.2019.03.001. [Epub ahead of print] Arginine vasopressin antagonism in heart failure: Current status and possible new directions. Goldsmith SR1. 7.Metabolism of Peptide Drugs and Strategies to Improve their Metabolic Stability 8.Expert Rev Neurother. 2017 Jan;17(1):59-75. Epub 2016 Oct 20. Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology. Tramutola A1, Arena A1,   [更多]

1.丙氨酰谷氨酰胺及其注射液的研究開發(fā) 2.A prospective multicentre study on the treatment of cardiovascular risk factors and claudication symptoms in patients with peripheral artery disease (the IDOMENEO study). Cimminiello C, Arpaia G, Polo Friz H, Boracchi P, Marano G, Spezzigu G, Visonà A. Vasa. 2015 Sep;44(5):371-9. doi: 10.1024/0301-1526/a000456. 3.2013 International Conference on Materials Engineering, ICMEN 2013 4.Orientation of substitution in the aromatic series. XVIII. Sulfonation of phenol by chlorosulfonic acid in solvents 5.Mechanism of reaction of chlorosulfonic acid with some aromatic compounds 6.Arzneimittelforschung. 1982;32(3):248-51. In vitro--in vivo correlation, a time scaling problem? Basic considerations on in vitro dissolution testing. 7.Oral treatment with the Crataegus special extract WS 1442 inhibits cardiac hypertrophy in rats with DOCA-salt or aortic banding induced hypertension   [更多]

1.Nakashima M, Morita J, Aizawa K. Pharamacokinetics and safety of tebipenem pivoxil fine granules, an oral carbapenem antibiotic, in healthy male volunteers. Jpn J Chemother. 2009;57(S–1):90–94 2.Baba S, Yamanaka N, Suzuki K, et al. Clinical efficacy, safety and PK-PD analysis of tebipenem pivoxil in a phase II clinical trial in otolaryngological infections. Jpn J Antibiot. 2009;62:155–177 3.Sunakawa K. Pharmacological properties and clinical performance of the novel oral carbapenem antimicrobial drug, “Tebipenem pivoxil” (Orapenem fine granules 10% for pediatric use). Jpn J Chemother. 2009;57:279–294 4.Yamanaka N, Furukawa M, Furuya, et al. Clinical efficacy of tebipenem pivoxil (ME1211), a novel oral carbapenem, in otolaryngological infections, a Phase II clinical trial (1). 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) 2005; Abstract L-577 5.Iwata S, Ouchi K, Iwata N, et al. An open clinical study of tebipenem pivoxil in children with bacterial pneumonia. Jpn J Chemother. 2009;57(S–1):137–150   [更多]

求DOF 2019年1-3期文獻   [更多]

求購氟吡草酮、砜吡草唑原藥各70kg，含量80%以上   [更多]

標(biāo)題：求購克拉霉素緩釋片USP41標(biāo)準(zhǔn) 詳細要求： 需求名稱：克拉霉素緩釋片標(biāo)準(zhǔn) 具體要求：USP42 要求時間：請在2019年05月15日之前 交稿方式：直接點擊交稿在線交稿就是了，我會每天過來看的，謝謝各位藥智的戰(zhàn)友們   [更多]

藥復(fù)核標(biāo)準(zhǔn)匯編(2003)中關(guān)于復(fù)方α-酮酸片的標(biāo)準(zhǔn)   [更多]